第一个结果来自多模式心身治疗方法-一项前瞻性纵向研究。

IF 3.5 2区医学 Q2 PSYCHIATRY

Journal of Psychosomatic Research Pub Date : 2025-02-01 DOI:10.1016/j.jpsychores.2024.112021

Hanna Hofmann , Angela Fricke , Benjamin Krüger , Paul Köbler , Claudia Lanza , Stephan Zeiß , Jan Cernohorsky , Christine Hertle , Eva Krauss-Köstler , Peter Radermacher , Barbara Stein , Markus Müller , Christiane Waller

{"title":"第一个结果来自多模式心身治疗方法-一项前瞻性纵向研究。","authors":"Hanna Hofmann , Angela Fricke , Benjamin Krüger , Paul Köbler , Claudia Lanza , Stephan Zeiß , Jan Cernohorsky , Christine Hertle , Eva Krauss-Köstler , Peter Radermacher , Barbara Stein , Markus Müller , Christiane Waller","doi":"10.1016/j.jpsychores.2024.112021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Clinical experiences using a psychosomatic-oriented multimodal treatment approach in patients with post-COVID are promising. We established a half-day multimodal treatment program for post-COVID patients at the Department of Psychosomatic Medicine at General Hospital Nuremberg, Paracelsus Medical University, Germany.</div></div><div><h3>Methods</h3><div>This observational study between January 2022 and March 2023 comprised baseline documentation of Patient Health Questionnaire (PHQ<img>D), ICD-10 Symptom Rating (ISR), Fatigue Scale (FS) and Health Status Questionnaire (SF-12) at admission and discharge of 65 patients suffering from post-COVID. Multimodal psychosomatic treatment was scheduled for 3–4 weeks.</div></div><div><h3>Results</h3><div>At admission, PHQ and FS showed a high level of somatic symptom burden (PHQ-15: <em>M</em> = 16.0, <em>SD</em> = 5.6) and fatigue symptoms (FS: <em>M</em> = 27.1, <em>SD</em> = 4.4). Depressive (PHQ-9: <em>M</em> = 14.0, <em>SD</em> = 5.3) and anxiety symptoms (GAD-7: <em>M</em> = 9.6, <em>SD</em> = 5.6) were moderately and mildly pronounced, respectively. Compared to patients from our standard clinical settings post-COVID patients had a comparably high or even higher mental symptom burden (e.g. PHQ-15: <em>p</em> < .001, <em>d</em> = 0.79; PHQ-9: <em>p</em> = .009, <em>d</em> = 0.39). Compared to admission, symptomatology of post-COVID patients at discharge was improved (e.g. PHQ-15: <em>p</em> = .004, <em>d</em> = 0.26; FS: <em>p</em> = .009, <em>d</em> = 0.32).</div></div><div><h3>Conclusions</h3><div>Despite the short duration of treatment, the patients showed a significant reduction in symptoms between admission and discharge. Further data including a control group and extending the duration of treatment will show whether the changes in symptoms are of the multimodal psychosomatic treatment.</div></div>","PeriodicalId":50074,"journal":{"name":"Journal of Psychosomatic Research","volume":"189 ","pages":"Article 112021"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"First results from a multimodal psychosomatic post-COVID treatment approach - a prospective longitudinal study\",\"authors\":\"Hanna Hofmann , Angela Fricke , Benjamin Krüger , Paul Köbler , Claudia Lanza , Stephan Zeiß , Jan Cernohorsky , Christine Hertle , Eva Krauss-Köstler , Peter Radermacher , Barbara Stein , Markus Müller , Christiane Waller\",\"doi\":\"10.1016/j.jpsychores.2024.112021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Clinical experiences using a psychosomatic-oriented multimodal treatment approach in patients with post-COVID are promising. We established a half-day multimodal treatment program for post-COVID patients at the Department of Psychosomatic Medicine at General Hospital Nuremberg, Paracelsus Medical University, Germany.</div></div><div><h3>Methods</h3><div>This observational study between January 2022 and March 2023 comprised baseline documentation of Patient Health Questionnaire (PHQ<img>D), ICD-10 Symptom Rating (ISR), Fatigue Scale (FS) and Health Status Questionnaire (SF-12) at admission and discharge of 65 patients suffering from post-COVID. Multimodal psychosomatic treatment was scheduled for 3–4 weeks.</div></div><div><h3>Results</h3><div>At admission, PHQ and FS showed a high level of somatic symptom burden (PHQ-15: <em>M</em> = 16.0, <em>SD</em> = 5.6) and fatigue symptoms (FS: <em>M</em> = 27.1, <em>SD</em> = 4.4). Depressive (PHQ-9: <em>M</em> = 14.0, <em>SD</em> = 5.3) and anxiety symptoms (GAD-7: <em>M</em> = 9.6, <em>SD</em> = 5.6) were moderately and mildly pronounced, respectively. Compared to patients from our standard clinical settings post-COVID patients had a comparably high or even higher mental symptom burden (e.g. PHQ-15: <em>p</em> < .001, <em>d</em> = 0.79; PHQ-9: <em>p</em> = .009, <em>d</em> = 0.39). Compared to admission, symptomatology of post-COVID patients at discharge was improved (e.g. PHQ-15: <em>p</em> = .004, <em>d</em> = 0.26; FS: <em>p</em> = .009, <em>d</em> = 0.32).</div></div><div><h3>Conclusions</h3><div>Despite the short duration of treatment, the patients showed a significant reduction in symptoms between admission and discharge. Further data including a control group and extending the duration of treatment will show whether the changes in symptoms are of the multimodal psychosomatic treatment.</div></div>\",\"PeriodicalId\":50074,\"journal\":{\"name\":\"Journal of Psychosomatic Research\",\"volume\":\"189 \",\"pages\":\"Article 112021\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Psychosomatic Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022399924004331\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychosomatic Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022399924004331","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

背景：以心身为导向的多模式治疗新冠肺炎后患者的临床经验是有希望的。我们在德国巴拉塞尔苏斯医科大学纽伦堡总医院心身医学部为新冠肺炎后患者建立了为期半天的多模式治疗方案。方法：本观察性研究于2022年1月至2023年3月期间对65例新冠肺炎患者入院和出院时的患者健康问卷（PHQD）、ICD-10症状评分（ISR）、疲劳量表（FS）和健康状况问卷（SF-12）进行基线记录。多模式心身治疗计划3-4周。结果：入院时，PHQ和FS表现出高水平的躯体症状负担（PHQ-15: M = 16.0, SD = 5.6）和疲劳症状（FS: M = 27.1, SD = 4.4）。抑郁症状（PHQ-9: M = 14.0, SD = 5.3）和焦虑症状（GAD-7: M = 9.6, SD = 5.6）分别为中度和轻度。与我们标准临床环境的患者相比，新冠肺炎后患者的精神症状负担相对较高，甚至更高（例如PHQ-15: p）。结论：尽管治疗时间较短，但患者入院和出院期间症状明显减轻。包括对照组和延长治疗时间在内的进一步数据将显示症状的变化是否属于多模式心身治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

First results from a multimodal psychosomatic post-COVID treatment approach - a prospective longitudinal study

Background

Clinical experiences using a psychosomatic-oriented multimodal treatment approach in patients with post-COVID are promising. We established a half-day multimodal treatment program for post-COVID patients at the Department of Psychosomatic Medicine at General Hospital Nuremberg, Paracelsus Medical University, Germany.

Methods

This observational study between January 2022 and March 2023 comprised baseline documentation of Patient Health Questionnaire (PHQD), ICD-10 Symptom Rating (ISR), Fatigue Scale (FS) and Health Status Questionnaire (SF-12) at admission and discharge of 65 patients suffering from post-COVID. Multimodal psychosomatic treatment was scheduled for 3–4 weeks.

Results

At admission, PHQ and FS showed a high level of somatic symptom burden (PHQ-15: M = 16.0, SD = 5.6) and fatigue symptoms (FS: M = 27.1, SD = 4.4). Depressive (PHQ-9: M = 14.0, SD = 5.3) and anxiety symptoms (GAD-7: M = 9.6, SD = 5.6) were moderately and mildly pronounced, respectively. Compared to patients from our standard clinical settings post-COVID patients had a comparably high or even higher mental symptom burden (e.g. PHQ-15: p < .001, d = 0.79; PHQ-9: p = .009, d = 0.39). Compared to admission, symptomatology of post-COVID patients at discharge was improved (e.g. PHQ-15: p = .004, d = 0.26; FS: p = .009, d = 0.32).

Conclusions

Despite the short duration of treatment, the patients showed a significant reduction in symptoms between admission and discharge. Further data including a control group and extending the duration of treatment will show whether the changes in symptoms are of the multimodal psychosomatic treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Psychosomatic Research 医学-精神病学

CiteScore

7.40

自引率

6.40%

发文量

314

审稿时长

6.2 weeks

期刊介绍： The Journal of Psychosomatic Research is a multidisciplinary research journal covering all aspects of the relationships between psychology and medicine. The scope is broad and ranges from basic human biological and psychological research to evaluations of treatment and services. Papers will normally be concerned with illness or patients rather than studies of healthy populations. Studies concerning special populations, such as the elderly and children and adolescents, are welcome. In addition to peer-reviewed original papers, the journal publishes editorials, reviews, and other papers related to the journal''s aims.